Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Clinical trial NCT04512716 · RECRUITING

Trial details

NCT number: NCT04512716
Sponsor: Memorial Sloan Kettering Cancer Center
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

B-ALL DLBCL B ALL Dlbcl-Ci DLBCL Unclassifiable DLBCL, Nos Genetic Subtypes DLBCL Activated B-Cell Type DLBCL Germinal Center B-Cell Type Diffuse Large B-cell Lymphoma HGBL HGBL, Nos

Start date: 2021-02-02
Primary completion: 2027-01-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.